Daratumumab or active monitoring for high-risk smoldering multiple myeloma

Last Updated: Wednesday, June 25, 2025

A phase 3 trial showed that subcutaneous daratumumab monotherapy significantly reduced the risk of progression to active multiple myeloma or death and improved overall survival in patients with high-risk smoldering multiple myeloma compared to active monitoring. This anti-CD38 antibody treatment had no new safety concerns.

The New England Journal of Medicine

European Journal of Haematology

From trials to practice: A 2025 review of idecabtagene vicleucel and ciltacabtagene autoleucel efficacy across clinical studies and real-world evidence

Advances in Hematology

Newly diagnosed high-risk multiple myeloma: Outcomes and management

Cureus

Dural-based plasmacytoma presenting as the initial sign of multiple myeloma

HemaSphere

Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN-HARMONY Alliance platform

Nature Reviews. Clinical Oncology

EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma

Discover Oncology

Deciphering and targeting oncogenic pathways through integrated approaches and amino acid metabolism in hematologic malignancies

The Journal of the American Academy of Orthopaedic Surgeons

Influence of chimeric antigen receptor T-cell therapy on fracture risk of patients with multiple myeloma

Cancer Nursing

Dynamic changes in symptom clusters and symptom networks in patients with multiple myeloma: Across-lagged network analysis

Clinical Lymphoma, Myeloma & Leukemia

Practical guidance on the clinical management of belantamab mafodotin for patients with relapsed/refractory multiple myeloma: Recommendations from the Middle East and North Africa expert panel

Future Oncology

Community hematologist/oncologist perspectives on minimal residual disease testing in patients with multiple myeloma

Multiple Myeloma Resource Center